Keros Therapeutics (KROS)
(Delayed Data from NSDQ)
$45.06 USD
-0.31 (-0.68%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $44.93 -0.13 (-0.29%) 7:44 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for Keros Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -152.99 | -104.68 | -58.74 | -45.36 | -12.34 |
Depreciation/Amortization & Depletion | 0.82 | 0.67 | 0.38 | 0.28 | 0.21 |
Net Change from Assets/Liabilities | -2.65 | 14.31 | -16.07 | 2.28 | -6.72 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 30.32 | 19.64 | 12.29 | 5.91 | 2.85 |
Net Cash From Operating Activities | -124.51 | -70.06 | -62.15 | -36.89 | -16.00 |
Property & Equipment | -2.46 | -1.24 | -1.02 | -0.29 | -0.27 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -2.46 | -1.24 | -1.02 | -0.29 | -0.27 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 179.05 | 120.40 | 28.55 | 299.24 | 0.01 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.09 | -0.09 | 0.00 | -3.20 | 0.00 |
Net Cash from Financing Activities | 178.96 | 120.31 | 28.55 | 296.04 | 0.01 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 51.98 | 49.01 | -34.62 | 258.86 | -16.26 |
Cash at Beginning of Period | 280.38 | 231.37 | 265.99 | 7.14 | 23.39 |
Cash at End of Period | 332.36 | 280.38 | 231.37 | 265.99 | 7.14 |
Diluted Net EPS | -5.20 | -4.15 | -2.52 | -2.93 | NA |
Fiscal Year End for Keros Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -88.37 | -43.11 | -152.99 | -112.75 | -73.31 |
Depreciation/Amortization & Depletion | 0.58 | 0.28 | 0.82 | 0.57 | 0.36 |
Net Change from Assets/Liabilities | -14.11 | -10.13 | -2.65 | -9.53 | -5.62 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 17.54 | 8.41 | 30.32 | 22.66 | 13.50 |
Net Cash From Operating Activities | -84.36 | -44.56 | -124.51 | -99.05 | -65.07 |
Property & Equipment | -1.26 | -0.95 | -2.46 | -1.92 | -1.37 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -1.26 | -0.95 | -2.46 | -1.92 | -1.37 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 160.66 | 157.06 | 179.05 | 109.73 | 109.42 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.32 | -0.26 | -0.09 | -0.03 | 0.00 |
Net Cash from Financing Activities | 160.33 | 156.80 | 178.96 | 109.70 | 109.42 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 74.72 | 111.30 | 51.98 | 8.73 | 42.98 |
Cash at Beginning of Period | 332.36 | 332.36 | 280.38 | 280.38 | 280.38 |
Cash at End of Period | 407.08 | 443.66 | 332.36 | 289.11 | 323.35 |
Diluted Net EPS | -1.25 | -1.21 | -1.34 | -1.33 | -1.27 |